Business
/C O R R E C T I O N from Source -- ARIUS Research Inc./
In c4202 transmitted on January 25, 2008, an error occurred in the information following the seco...
About this update from Affinity Metals Corp
[{"type":"text","content":"\n\n\n\nIn c4202 transmitted on January 25, 2008, an error occurred in the\ninformation following the second paragraph. The "TAPED REPLAY" phone numbers\nshould have been titled the "DIAL-IN NUMBERS" and the sentence that read\n"(Available until February 5, 2008)" should NOT have been included. Corrected\ncopy follows:\n\n\nARIUS to Hold Fourth Quarter and Year End 2007 Conference Call\n\n\nTORONTO, Jan. 25 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology\ncompany discovering and developing the next wave of antibody therapeutics,\ntoday announced it will hold a conference call to discuss its fourth quarter\nand year end 2007 results at 8:00 a.m. (Eastern Time) on Tuesday, January 29,\n2008. The Company will report its results in a press release to be issued at\n7:00 a.m. prior to the call.\n\n\nDATE: Tuesday, January 29, 2008\n\nTIME: 8:00 a.m., Eastern Standard Time\n\nWEBCAST: A live audio webcast of the call will be available at\nwww.ariusmabs.com. Webcast attendees are welcome to listen to the conference\nin real-time or on-demand at their convenience. The webcast will be archived\nfor 365 days. Please connect to this website at least 15 minutes prior to the\nconference call to ensure adequate time for any software download that may be\nneeded to hear the webcast.\n\nDIAL-IN NUMBERS: 416-644-3414 or 1-800-731-6941\n\nREFERENCE NUMBER: 21261080\n\n\nAbout ARIUS\n\n\nARIUS is a biotechnology company discovering and developing the next wave\nof antibody therapeutics. Established in 1999, ARIUS has built a proprietary\ntechnology platform, FunctionFIRST(TM), that rapidly identifies and selects\nantibodies based on their functional ability to affect disease. This antibody\ngeneration engine has enabled ARIUS to assemble a portfolio of more than 500\nantibody candidates. In addition to the antibodies it is developing in-house,\nARIUS has ongoing partnerships with key biotechnology and drug development\ncompanies. ARIUS is listed on the TSX under the symbol "ARI". For further\ninformation, visit www.ariusmabs.com\n\n\nForward-Looking Statements\n\n\nCertain statements in this news release constitute "forward-looking\nstatements" within the meaning of the Private Securities Litigation Reform Act\nof 1995, which involve known and unknown risks, uncertainties and other\nfactors...